Skip to Content
Merck
CN

10385

Angiotensin III trifluoroacetate salt hydrate

≥98% (HPCE)

Synonym(s):

Des-Asp-1-Angiotensin II trifluoroacetate salt hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C46H66N12O9 · xC2HF3O2 · yH2O
CAS Number:
12687-51-3
Molecular Weight:
931.09 (anhydrous free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77
PubChem Substance ID:
57646800
MDL number:
MFCD20264812
Beilstein/REAXYS Number:
8385695

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Angiotensin III trifluoroacetate salt hydrate, ≥98% (HPCE)

InChI

1S/C46H66N12O9.C2HF3O2.H2O/c1-5-27(4)38(57-40(61)33(21-29-15-17-31(59)18-16-29)53-42(63)37(26(2)3)56-39(60)32(47)13-9-19-51-46(48)49)43(64)54-34(23-30-24-50-25-52-30)44(65)58-20-10-14-36(58)41(62)55-35(45(66)67)22-28-11-7-6-8-12-28;3-2(4,5)1(6)7;/h6-8,11-12,15-18,24-27,32-38,59H,5,9-10,13-14,19-23,47H2,1-4H3,(H,50,52)(H,53,63)(H,54,64)(H,55,62)(H,56,60)(H,57,61)(H,66,67)(H4,48,49,51);(H,6,7);1H2/t27-,32-,33-,34-,35-,36-,37-,38-;;/m0../s1

SMILES string

O.OC(=O)C(F)(F)F.CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N3CCC[C@H]3C(=O)N[C@@H](Cc4ccccc4)C(O)=O

InChI key

JEOAJMGVSAMVML-UFPGTABSSA-N

assay

≥98% (HPCE)

solubility

H2O: 1.0 mg/mL, clear, colorless

storage temp.

−20°C

Quality Level

100

Biochem/physiol Actions

Angiotensin III is an AT1 and AT2 agonist, with higher sensitivity for the AT2 receptor. Ang III has been shown to be a main effector peptide in RAS-controlled vasopresin release and a stimulator for aldosterone release.

Features and Benefits

This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

General description

Angiotensin III (Ang III) is a 7-AA bioactive peptide that is formed from the degradation of the Angiotensin II peptide by aminopeptidase A; both are derivatives of angiotensinogen and are components of the renin-angiotensin system (RAS).
Arg-Val-Tyr-Ile-His-Pro-Phe-OH.3CH3COOH.4H2O

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCM9038
BCCK4410
BCCK2388
BCCG8894
BCCG0845

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nadja Grobe et al.
American journal of physiology. Endocrinology and metabolism, 302(8), E1016-E1024 (2012-02-10)
To better understand the tissue distribution and activity of enzymes involved in angiotensin II (Ang II) processing, we developed a novel molecular imaging method using matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry. Mouse kidney sections (12 μm) were incubated with
Els Moltzer et al.
Hypertension (Dallas, Tex. : 1979), 55(2), 516-522 (2009-12-23)
Because angiotensin (Ang) metabolites mediate functions independent of Ang II, we investigated their effects on coronary flow in spontaneously hypertensive rats (SHRs). Results were compared with those in the iliac artery and abdominal aorta and the coronary circulation of the
Focus on Brain Angiotensin III and Aminopeptidase A in the Control of Hypertension
Wright, J.W., et al.
International Journal of Hypertension, doi: 10-doi: 10 (2011)
Yannick Marc et al.
Progress in neurobiology, 95(2), 89-103 (2011-07-19)
Hypertension affects 26% of adults and is in constant progress related to increased incidence of obesity and diabetes. One-third of hypertensive patients may be successfully treated with one antihypertensive agent, one-third may require two agents and in the remaining patients
Bing S Huang et al.
Cardiovascular research, 97(3), 424-431 (2012-12-22)
In rats post-myocardial infarction (MI), activation of angiotensinergic pathways in the brain contributes to sympathetic hyperactivity and progressive left ventricle (LV) dysfunction. The present study examined whether angiotensin III (Ang III) is one of the main effector peptides of the
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service